[Evaluation of cefpodoxime proxetil in the pediatric field]. 1989

K Niino, and H Sato, and A Narita, and S Nakazawa, and H Suzuki, and K Matsumoto, and S Nakazawa
Department of Pediatrics, Oquchi Higashi General Hospital.

Pharmacokinetic and clinical evaluation of cefpodoxime proxetil (CPDX-PR, CS-807) were performed in the field of pediatrics. The obtained results are summarized as follows. 1. Peak serum concentrations of CPDX upon single oral doses of 3.0 mg/kg and 4.4 mg/kg of CPDX-PR were 1.26-1.46 micrograms/ml and 1.45 micrograms/ml, respectively, achieved at 4 hours and 1 hour after administration. Urinary excretion rates for CPDX in the first 8 hours ranged between 28.1 and 30.2%. 2. Clinical efficacy rates for pediatric infections obtained at single dose levels ranging 3 to 6 mg/kg were 97.5%, and that at a single dose of 1 mg/kg were 90.9%. 3. Bacteriological effectiveness was determined in 45 strains identified in recent cases. Eradication rates for these bacteria at dose levels of 3 to 6 mg/kg and 1 mg/kg were 91.3% and 95.5%, respectively. 4. No side effect nor abnormal laboratory test data were found in any of the cases examined. From these results, CPDX-PR appeared to be a useful antibiotic agent in the field of pediatrics.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D001991 Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI. Bronchitides
D002621 Chemistry A basic science concerned with the composition, structure, and properties of matter; and the reactions that occur between substances and the associated energy exchange.
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Niino, and H Sato, and A Narita, and S Nakazawa, and H Suzuki, and K Matsumoto, and S Nakazawa
July 1989, The Japanese journal of antibiotics,
K Niino, and H Sato, and A Narita, and S Nakazawa, and H Suzuki, and K Matsumoto, and S Nakazawa
July 1989, The Japanese journal of antibiotics,
K Niino, and H Sato, and A Narita, and S Nakazawa, and H Suzuki, and K Matsumoto, and S Nakazawa
January 1991, Drugs,
K Niino, and H Sato, and A Narita, and S Nakazawa, and H Suzuki, and K Matsumoto, and S Nakazawa
July 1989, The Japanese journal of antibiotics,
K Niino, and H Sato, and A Narita, and S Nakazawa, and H Suzuki, and K Matsumoto, and S Nakazawa
July 1989, The Japanese journal of antibiotics,
K Niino, and H Sato, and A Narita, and S Nakazawa, and H Suzuki, and K Matsumoto, and S Nakazawa
September 1994, The Japanese journal of antibiotics,
K Niino, and H Sato, and A Narita, and S Nakazawa, and H Suzuki, and K Matsumoto, and S Nakazawa
July 1989, The Japanese journal of antibiotics,
K Niino, and H Sato, and A Narita, and S Nakazawa, and H Suzuki, and K Matsumoto, and S Nakazawa
January 2019, Profiles of drug substances, excipients, and related methodology,
K Niino, and H Sato, and A Narita, and S Nakazawa, and H Suzuki, and K Matsumoto, and S Nakazawa
March 1993, Pediatric annals,
K Niino, and H Sato, and A Narita, and S Nakazawa, and H Suzuki, and K Matsumoto, and S Nakazawa
November 1995, Journal of chemotherapy (Florence, Italy),
Copied contents to your clipboard!